2022
Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)
Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525). Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.Peer-Reviewed Original ResearchHospice servicesBlood cancersHospice useHematologic malignanciesUtility scoresAdvanced hematologic malignanciesBlood cancer patientsCaregiver focus groupsAdult patientsBlood transfusionMedian ageCancer CenterCancer patientsAcute leukemiaHospice modelValue patientsMedical appointmentsCancer placesPatientsRespite careWeb-based surveyTransfusionCancerCognitive debriefingMalignancy
2021
Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies
Odejide O, Huntington S, Kuczmarski T, Shi E, Tulsky J, Abel G. Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies. Blood 2021, 138: 4026. DOI: 10.1182/blood-2021-153361.Peer-Reviewed Original ResearchHealthcare teamPrognostic discussionsHematologic oncologistsBlood cancersUnivariable analysisLife expectancyHematologic malignanciesAdvanced hematologic malignanciesHalf of patientsCohort of patientsLarge cancer centerPerceptions of prognosisBlood cancer patientsAccurate prognostic understandingEnd of lifeAdult patientsCommon diagnosisMedian timeOutpatient visitsCancer CenterCancer patientsPrognostic understandingAcute leukemiaPatients' perceptionsOwn life expectancyPerceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey
Odejide O, Huntington S, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey. Blood 2021, 138: 3020. DOI: 10.1182/blood-2021-153304.Peer-Reviewed Original ResearchBlood cancersCancer CenterHematologic malignanciesHospice servicesUtility scoresLarge cancer centerConfidence intervalsPerceptions of patientsBlood cancer patientsPerspectives of patientsDays of lifeYears of ageQuality of lifeCaregiver focus groupsEligible patientsHematologic oncologistsBlood transfusionMedian ageCommon diagnosisOutpatient visitsCancer patientsHospice useStudy inclusionAcute leukemiaPatients' perceptions
2020
Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.
Davidoff A, Long J, Huntington S. Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies. Journal Of Clinical Oncology 2020, 38: 38-38. DOI: 10.1200/jco.2020.38.29_suppl.38.Peer-Reviewed Original ResearchLines of therapyCare settingsNon-teaching hospitalsHematologic malignanciesSEER-MedicareContinuous Medicare Parts AMajor cancer sitesMultivariable logistic regressionNew immunomodulatory drugsMultiple myeloma therapyEnd of studyMedicare Part ANCI cancer centersFit patientsCell transplantDiagnosis yearImmunomodulatory drugsTreatment patternsMM diagnosisCancer CenterPatient populationCancer sitesMyeloma therapyAcademic hospitalLower odds
2018
Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.Peer-Reviewed Original ResearchHMA cyclesOverall survivalHMA initiationHMA therapyMyelodysplastic syndromeProvider typeCancer CenterMD volumeMultivariate Cox proportional hazardsKaplan-Meier log-rank testAZA-001 trialMedian overall survivalTwo-sided statistical testsLog-rank testReal-world survivalCox proportional hazardsLogistic regression analysisWilcoxon rank sum testChi-square testCommunity-based practiceRank sum testEligible ptsLookback periodEarly discontinuationAgent therapy